Free Access
Tableau 1
Récepteurs inhibiteurs des cellules NK qui font l’objet d’une thérapie ciblée.
| Cible | Ligand | Médicament | Status |
|---|---|---|---|
| KIR2DL1/2/3 | HLA-C | Lirilumab | Phase II |
| NKG2A | HLA-E | Monalizumab | Phase II |
| PD1 | PD-L1/-L2 | BMS/ONO : nivolumab, Merck : pembrolizumab Regeneron/ Sanofi : cemiplimab Novartis : PDR001 AZN : MEDI0680 Janssen : JNJ-63723283 Pfizer : PF-06801591 Agenus/Incyte : INCSHR1210 |
Disponible (Opdivo®) Disponible (Keytruda®) Disponible (Libtayo®) Phase II Phase I/II Phase I/II Phase I Phase I |
| PD-L1 | PD1 | Roche : atézolizumab, AZN : durvalumab Pfizer/Merck Kga : avélumab Eli Lilly: LY3300054 |
Disponible (Técentriq®) Disponible (Imfinzi®) Disponible (Bavencio®) phase I |
| LAG-3 | HLA-II | BMS : BMS-986016 Prima BioMed: IMP321 Novartis : LAG525 Anaptys/Tesaro Merck Regeneron/Sanofi Macrogenics (PD-1 bispecific) |
Phase II phase I/II Phase I Préclinique Préclinique Préclinique Préclinique |
| TIM-3 | Gal-9, CEACAM1, Phosphatidylsérine, LILRB2 |
Novartis : MBG453 Anaptys/Tesaro : TS-022 Jounce/ Celgene Roche |
Phase I Phase I Préclinique Préclinique |
| TIGIT | CD155, CD112 | OMP: OMP-313M32 Roche Merck BMS |
Phase I Phase I Préclinique Préclinique |
| VISTA | Inconnu | Janssen : JNJ-61610588 Igenica : IGN381 |
Phase I Préclinique |
| Inconnue | B7-H3 | Énoblituzumab | Phase I |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.